Novel anticancer agent, SQAP, binds to focal adhesion kinase and modulates its activity

新型抗癌剂 SQAP 可与粘着斑激酶结合并调节其活性

阅读:9
作者:Jesus Izaguirre-Carbonell, Hirofumi Kawakubo, Hiroshi Murata, Atsushi Tanabe, Toshifumi Takeuchi, Tomoe Kusayanagi, Senko Tsukuda, Takeshi Hirakawa, Kazuki Iwabata, Yoshihiro Kanai, Keisuke Ohta, Masahiko Miura, Kengo Sakaguchi, Sachihiro Matsunaga, Hiroeki Sahara, Shinji Kamisuki, Fumio Sugawara

Abstract

SQAP is a novel and promising anticancer agent that was obtained by structural modifications from a natural compound. SQAP inhibits angiogenesis in vivo resulting in increased hypoxia and reduced tumor volume. In this study, the mechanism by which SQAP modifies the tumor microenvironment was revealed through the application of a T7 phage display screening. This approach identified five SQAP-binding proteins including sterol carrier protein 2, multifunctional enzyme type 2, proteasomal ubiquitin receptor, UV excision repair protein and focal adhesion kinase (FAK). All the interactions were confirmed by surface plasmon resonance analysis. Since FAK plays an important role in cell turnover and angiogenesis, the influence of SQAP on FAK was the principal goal of this study. SQAP decreased FAK phosphorylation and cell migration in human umbilical vein endothelial cells and A549 cancer cells. These findings suggest that inhibition of FAK phosphorylation works as the mechanism for the anti-angiogenesis activity of SQAP.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。